MONTE ROSA THERAPEUTIC

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

31 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

08 Jan 2024 07:15:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

21 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

09 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

07 Nov 2023 10:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

27 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

26 Oct 2023 16:30:50 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

10 Aug 2023 07:15:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

26 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences

30 May 2023 16:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

23 May 2023 07:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 07:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023

17 Apr 2023 16:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

23 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

16 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

03 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

09 Jan 2023 07:30:00 By Nasdaq GlobeNewswire